olatorepatide
Peptide
Also known as HS-20094
Evidence outlook · regulatory review
Obesity: application under NMPA review
NMPA accepts olatorepatide NDA (2026-06). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT06839664: This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Type 2 Diabetes · Phase 3Hidradenitis Suppurativa · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07431086 NCT07431086 · Overweight or Obesity Registry: NCT07431086 | 2 | Occurrence of Treatment-Emergent Adverse Events (TEAEs) (Up to approximately 30 weeks); Severity of TEAEs (Up to approximately 30 weeks); Maximum plasma Concentration (Cmax) (At week 15 and week 24); Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h) (At week 15 and week 24) 2026-11-13 | In progress: primary completion was expected 13 Nov 2026; results not posted | not yet graded | link ↗ |
View 2 more trials
NCT07685808 NCT07685808 · Overweight or Obesity Registry: NCT07685808 | 2 | Occurrence of Treatment-Emergent Adverse Events (TEAEs) (Up to approximately 60 weeks); Severity of TEAEs (Up to approximately 60 weeks); Percent change in body weight (From baseline to week 52) 2028-01-21 | In progress: results expected 21 Jan 2028 | not yet graded | link ↗ |
NCT06839664 NCT06839664 · Overweight, Obesity This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06839664 | 3 | Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48) 2026-01-04 | Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other GLP-1/GIP receptor (dual) drugs
Tirzepatide (Mounjaro), Tirzepatide (Zepbound), BGM0504, Brenipatide, enicepatide and 7 more. Compare all 13 GLP-1/GIP receptor (dual) drugs
This mechanism is crowded: 12 other tracked programmes target it, 2 of them ahead of this one.
This drug's own stage for Hidradenitis Suppurativa: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Olatorepatide: this drug | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Partial signal | NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Partial signal | NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants | |
| Lutikizumab | Phase 3 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2/3 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Spesolimab (Spevigo) | Phase 2/3 | Monoclonal antibody | IL-36 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Abdakibart | Phase 2 | Monoclonal antibody | IL-1 beta | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Eltrekibart | Phase 2 | Monoclonal antibody | CXCR1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| ORKA-002 | Phase 2 | Monoclonal antibody | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| SAR442970 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SAR445399 | Phase 2 | Monoclonal antibody | IL-1R3 (IL1RAP) | not yet graded | No reviewed efficacy summary in this indication | |
| SPY072 | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Zasocitinib | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1451 | Phase 1(overall) | Undisclosed | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| KP405 | Phase 1(overall) | Peptide | GLP-1/GIP receptor (dual) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SAR447971 | Phase 1(overall) | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipasertideg | Discontinued | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow olatorepatide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (3)
January 2028 (1)
November 2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent